Total Payments
$461,099
2024 Payments
$49,667
Companies
18
Transactions
421
Medicare Patients
733
Medicare Billing
$140,340
Payment Breakdown by Category
Other$334,170 (72.5%)
Consulting$78,935 (17.1%)
Travel$36,629 (7.9%)
Food & Beverage$11,348 (2.5%)
Education$16.80 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $306,540 | 112 | 66.5% |
| Consulting Fee | $78,935 | 32 | 17.1% |
| Travel and Lodging | $36,629 | 105 | 7.9% |
| Honoraria | $14,010 | 13 | 3.0% |
| Food and Beverage | $11,348 | 152 | 2.5% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $7,400 | 2 | 1.6% |
| Compensation for serving as faculty or as a speaker for a medical education program | $6,220 | 4 | 1.3% |
| Education | $16.80 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $276,152 | 249 | $0 (2024) |
| ABBVIE INC. | $86,103 | 83 | $0 (2024) |
| INTERCEPT PHARMACEUTICALS, INC. | $27,417 | 24 | $0 (2022) |
| Mallinckrodt Hospital Products Inc. | $26,710 | 17 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $16,516 | 19 | $0 (2018) |
| Madrigal Pharmaceuticals | $9,312 | 4 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $6,354 | 7 | $0 (2018) |
| Ipsen Biopharmaceuticals, Inc | $2,905 | 1 | $0 (2023) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $2,730 | 2 | $0 (2020) |
| GlaxoSmithKline, LLC. | $2,000 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $49,667 | 44 | Gilead Sciences, Inc. ($34,502) |
| 2023 | $51,940 | 39 | Gilead Sciences, Inc. ($20,940) |
| 2022 | $48,633 | 30 | Gilead Sciences, Inc. ($31,363) |
| 2021 | $47,236 | 35 | Gilead Sciences, Inc. ($31,475) |
| 2020 | $28,319 | 23 | Gilead Sciences, Inc. ($20,539) |
| 2019 | $58,344 | 66 | Gilead Sciences, Inc. ($27,719) |
| 2018 | $72,632 | 68 | Gilead Sciences, Inc. ($47,966) |
| 2017 | $104,329 | 116 | Gilead Sciences Inc ($61,648) |
All Payment Transactions
421 individual payment records from CMS Open Payments — Page 1 of 17
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/18/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $130.04 | General |
| 11/16/2024 | Gilead Sciences, Inc. | Livdelzi (Drug) | Food and Beverage | In-kind items and services | $144.84 | General |
| Category: INFLAM | ||||||
| 11/14/2024 | Mallinckrodt Hospital Products Inc. | TERLIVAZ (Drug) | Food and Beverage | In-kind items and services | $140.53 | General |
| Category: CRITICAL CARE | ||||||
| 09/24/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,173.00 | General |
| Category: LIVER DISEASE | ||||||
| 09/24/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $126.69 | General |
| Category: LIVER DISEASE | ||||||
| 09/24/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | Cash or cash equivalent | $20.00 | General |
| Category: LIVER DISEASE | ||||||
| 09/17/2024 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,370.00 | General |
| 09/13/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,992.50 | General |
| Category: LIVER DISEASE | ||||||
| 07/01/2024 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $6,190.00 | General |
| 06/27/2024 | Boston Scientific Corporation | — | Food and Beverage | In-kind items and services | $103.60 | General |
| Category: General - Biliary Devices_ENDO | ||||||
| 06/21/2024 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $171.29 | General |
| 06/21/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $22.52 | General |
| 06/21/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $14.57 | General |
| 06/21/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $9.75 | General |
| 06/20/2024 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $671.95 | General |
| 06/20/2024 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $345.14 | General |
| 06/20/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $132.34 | General |
| 06/20/2024 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $95.22 | General |
| 06/20/2024 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $74.58 | General |
| 06/20/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $59.81 | General |
| 06/20/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $7.37 | General |
| 05/28/2024 | Gilead Sciences, Inc. | Epclusa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,790.00 | General |
| Category: HCV | ||||||
| 05/08/2024 | Gilead Sciences, Inc. | Epclusa (Drug) | Travel and Lodging | In-kind items and services | $548.09 | General |
| Category: HCV | ||||||
| 05/08/2024 | Gilead Sciences, Inc. | Epclusa (Drug) | Food and Beverage | In-kind items and services | $118.99 | General |
| Category: HCV | ||||||
| 04/10/2024 | Gilead Sciences, Inc. | Vemlidy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,190.00 | General |
| Category: HBV | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 143 | 222 | $127,165 | $23,272 |
| 2022 | 6 | 213 | 372 | $217,890 | $39,007 |
| 2021 | 6 | 215 | 375 | $206,855 | $44,147 |
| 2020 | 7 | 162 | 353 | $186,065 | $33,913 |
Total Patients
733
Total Services
1,322
Medicare Billing
$140,340
Procedure Codes
26
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 53 | 53 | $45,610 | $9,677 | 21.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 23 | 81 | $40,500 | $5,845 | 14.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 11 | 12 | $8,880 | $2,017 | 22.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 12 | 12 | $7,455 | $1,593 | 21.4% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 14 | 34 | $10,880 | $1,557 | 14.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 16 | 16 | $7,820 | $1,507 | 19.3% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 14 | 14 | $6,020 | $1,078 | 17.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 79 | 79 | $62,170 | $14,892 | 24.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 36 | 131 | $69,250 | $7,945 | 11.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 22 | 76 | $43,300 | $6,584 | 15.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 53 | 62 | $29,080 | $6,549 | 22.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 12 | 13 | $9,360 | $2,017 | 21.5% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 11 | 11 | $4,730 | $1,021 | 21.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 67 | 67 | $50,520 | $13,331 | 26.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 30 | 127 | $69,850 | $12,186 | 17.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 43 | 60 | $24,600 | $6,824 | 27.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 35 | 36 | $20,785 | $5,549 | 26.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 20 | 65 | $32,500 | $4,345 | 13.4% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 20 | 20 | $8,600 | $1,913 | 22.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 39 | 203 | $111,650 | $19,697 | 17.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 48 | 55 | $28,300 | $4,460 | 15.8% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 16 | 16 | $9,005 | $2,296 | 25.5% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 11 | 11 | $8,100 | $1,984 | 24.5% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 13 | 15 | $8,550 | $1,944 | 22.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 11 | 27 | $13,500 | $1,791 | 13.3% |
About Dr. Paul Gaglio, MD
Dr. Paul Gaglio, MD is a Gastroenterology healthcare provider based in Newark, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1376583492.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Paul Gaglio, MD has received a total of $461,099 in payments from pharmaceutical and medical device companies, with $49,667 received in 2024. These payments were reported across 421 transactions from 18 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($306,540).
As a Medicare-enrolled provider, Gaglio has provided services to 733 Medicare beneficiaries, totaling 1,322 services with total Medicare billing of $140,340. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Other Specialties Hepatology, Transplant Hepatology
- Location Newark, NJ
- Active Since 06/07/2006
- Last Updated 11/14/2024
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1376583492
Products in Payments
- Epclusa (Drug) $129,772
- Vemlidy (Drug) $83,247
- Mavyret (Drug) $45,646
- MAVYRET (Drug) $25,066
- TERLIVAZ (Drug) $22,420
- OCALIVA (Drug) $17,142
- REZDIFFRA (Drug) $9,312
- Viekira (Drug) $8,248
- OCA (Drug) $6,636
- OPDIVO (Biological) $6,354
- Vosevi (Drug) $4,762
- ZEPATIER (Drug) $4,460
- Bylvay (Drug) $2,905
- XIFAXAN (Drug) $2,100
- PreHevbrio (Drug) $1,810
- Mulpleta (Drug) $766.80
- Harvoni (Drug) $680.00
- TRULANCE (Drug) $630.00
- Livdelzi (Drug) $144.84
- SIR-Spheres Microspheres (Device) $138.85
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Newark
Zamir Brelvi, M.d, M.D
Gastroenterology — Payments: $444,610
Gastroenterology $444,610
Gaurav Jain, Md, MD
Gastroenterology — Payments: $10,281
Gastroenterology $10,281
Dr. Jared Hossack, M.d, M.D
Gastroenterology — Payments: $10,266
Gastroenterology $10,266
Jorge Uribe, Md, MD
Gastroenterology — Payments: $10,111
Gastroenterology $10,111
Dr. Ghulam Mujtaba, Md, MD
Gastroenterology — Payments: $8,181
Gastroenterology $8,181
Dr. Christine Herdman
Gastroenterology — Payments: $7,911
Gastroenterology $7,911